GSK Strengthens Case for Blenrep’s Return in Multiple Myeloma Treatment

1. Positive Trial Results: GSK's Blenrep has shown significant delays in disease progression or death compared to Velcade and Darzalex in combination with Pomalyst and a steroid in multiple myeloma patients who have received at least one prior line of therapy.
2. DREAMM-8 Trial: The trial demonstrated a 48% reduction in the relative risk of disease progression or death compared to Velcade in the same combination, with a median progression-free survival of nearly two years for Blenrep patients.
3. DREAMM-7 Trial: The trial showed a 59% reduction in the relative risk of progression compared to Darzalex in the same combination, with a median progression-free survival of 37 months for Blenrep patients.
4. Improved Side Effect Management: Physicians have learned to manage Blenrep's eye-related side effects better through dose reductions and the use of lubricating or moisturizing eye drops, making the drug more manageable.
5. Potential Reauthorization: GSK plans to file Blenrep with the FDA in the second half of 2024, hoping to reintroduce the drug in the U.S. following a market withdrawal in 2022.
6. Competition: Blenrep will compete with CAR-T therapies like Carvykti and Abecma, which have shown strong results in multiple myeloma treatment.